Zealand Pharma A/S ZEAL:CPH Actions Health CarePharmaceuticals and Biotechnology Price (DKK)783.50 Today's Change13.50 / 1.75% Shares traded40.49k 1 Year change+120.08% Beta0.9951 Data delayed at least 15 minutes, as of Dec 10 2024 10:36 GMT....
Zealand Pharma reports Breakthrough Therapy designation for survodutide Oct. 8, 2024 at 5:20 a.m. ETon TipRanks.com Zealand Pharma initiated with a Hold at Deutsche Bank Oct. 2, 2024 at 4:35 a.m. ETon TipRanks.com Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, He...
Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax ApprovedAvisol Capital PartnersMon, Jun. 11, 20188 Comments Zealand Pharma: Partnerships And Looming Catalysts Make This A BuyJonathan FaisonMon, Jan. 08, 201814 Comments Share your Analysis on ZEALSubmit an article now ZEAL News Zea...
Frederik Barfoed Beck occupies the position of Director & Senior Manager-Outsourcing at Zealand Pharma A. Insider Actions Most Recent Insider Transactions Date Type Shareholder Title Transaction Type Share Price Shares Value Mar 7, 2023 Sale Frederik Barfoed Beck Disposition $234.60 PER SHARE -4,...
Latest Zealand Pharma A/S (22Z:FRA) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of...
picks analysis by sector energy communication services real estate consumer staples tech basic materials healthcare consumer utilities financials industrials stock comparison tools faang stocks gold etfs cash equivalents big bank stocks big pharma stocks retail stocks top indexes dow jones s&p 500 nasdaq ...
Along with significant pharmaceutical merchants and distributors, Australia is also home to worldwide pharmaceutical and biotechnology firms such as CSL and Mayne Pharma. All the factors mentioned above are likely to boost the demand for the market studied across Australia in the coming years. Get ...
2023. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection andPEDMARQSIhas received Pediatric Use Marketing Authorization inEuropewhich includes eight years plus two years of data and market prote...
This complex environment leaves little scope for 'traditional' generics companies competing solely on price. Indeed, mergers and acquisitions have brought forth a small number of multinational generics majors, with technological, legal, and marketing capabilities approximating those of 'big pharma'. Firms...